Alzheimer’s Disease

Home>Tag:Alzheimer's Disease
Jul 22 2021

Halberd Corp. Advances the Elimination of Antigens Present in Alzheimer’s Disease & PTSD/Chronic Traumatic Encephalopathy

By |2021-07-21T19:48:45-04:00July 22nd, 2021|Featured, Investor News, News|0 Comments

Jackson Center, PA, July 22, 2021 – Halberd Corporation (OTC-PINK: "HALB") confirms the shipment of samples of metallic nanoparticles conjugated to Alzheimer’s Disease (AD) antibodies, Tau and Phosphorylated Tau.  Having successfully conjugated the metallic nanoparticles (via its breakthrough patent-pending process), GreenBioAZ shipped the materials to Youngstown State University (YSU).  At YSU, Dr. William G. Sturrus, ...

Jun 30 2021

Halberd Corp. Discovers a Proprietary Disease-Causing Antigen Removal Process

By |2021-06-29T23:00:53-04:00June 30th, 2021|Featured, Investor News, News|0 Comments

Method Does Not Require Antibody Conjugated Metallic Nanoparticles Jackson Center, PA, June 30, 2021 – Halberd Corporation (OTC-PINK: "HALB") announces a possible breakthrough method for the removal of the disease-causing antigen(s) that does not require the use of metallic nanoparticles conjugated to antibodies.  This simplified method for the removal of disease-causing antigen(s) utilizes more conventional ...

Jun 21 2021

Halberd Corporation’s Proprietary Technology for Alzheimer’s Disease Enters Stage 4 of 7 Stage Process

By |2021-06-20T21:56:56-04:00June 21st, 2021|Featured, Investor News, News|0 Comments

Jackson Center, PA, June 21, 2021 – Halberd Corporation’s (OTC-PINK: "HALB") proprietary technology enters stage 4 to address Alzheimer’s Disease (and other potential diseases); eradicating the antibody-disease combination through radiofrequency waves or laser or other means.  Currently, there is no known effective treatment for Alzheimer’s Disease which afflicts over 40 million people worldwide, equivalent to ...

Jun 16 2021

Halberd Corporation Successfully Conjugates Metallic Particles and Antibodies Against Alzheimer’s Disease-Associated Antigens

By |2021-06-15T21:04:24-04:00June 16th, 2021|Featured, Investor News, News|0 Comments

Enables Extracorporeal Eradication of Pathogens from Cerebral Spinal Fluid Via Radio Frequency and/or Laser Emissive Energy Jackson Center, PA, June 16, 2021 – Halberd Corporation (OTC-PINK: "HALB") has successfully conjugated, Tau, Phosphorylated Tau and Beta Amyloid antibodies with gold-coated iron oxide nanoparticles in a patent-pending process.  These three antigens, which are found in Cerebral Spinal ...

Jun 9 2021

Halberd Corporation Undertakes Process Toward the Elimination of Alzheimer’s Disease

By |2021-06-08T21:47:47-04:00June 9th, 2021|Featured, Investor News, News|0 Comments

Jackson Center, PA, June 9, 2021 – Halberd Corporation (OTC-PINK: "HALB") commences experimentations to eradicate three of the principal components of Alzheimer’s Disease.  By eliminating these three critical antigens, which form the basis for neurofibrillary tangles in the brain, Halberd believes that its patented extracorporeal treatment process can slow or stop the progress of the ...

Go to Top